Department of Computer and Data Sciences, Case Western Reserve University, Cleveland, OH.
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH.
JCO Clin Cancer Inform. 2022 May;6:e2100156. doi: 10.1200/CCI.21.00156.
Allogenic hematopoietic stem-cell transplant (HCT) is a curative therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Relapse post-HCT is the most common cause of treatment failure and is associated with a poor prognosis. Pathologist-based visual assessment of aspirate images and the manual myeloblast counting have shown to be predictive of relapse post-HCT. However, this approach is time-intensive and subjective. The premise of this study was to explore whether computer-extracted morphology and texture features from myeloblasts' chromatin patterns could help predict relapse and prognosticate relapse-free survival (RFS) after HCT.
In this study, Wright-Giemsa-stained post-HCT aspirate images were collected from 92 patients with AML/MDS who were randomly assigned into a training set ( = 52) and a validation set ( = 40). First, a deep learning-based model was developed to segment myeloblasts. A total of 214 texture and shape descriptors were then extracted from the segmented myeloblasts on aspirate slide images. A risk score on the basis of texture features of myeloblast chromatin patterns was generated by using the least absolute shrinkage and selection operator with a Cox regression model.
The risk score was associated with RFS in (hazard ratio = 2.38; 95% CI, 1.4 to 3.95; = .0008) and (hazard ratio = 1.57; 95% CI, 1.01 to 2.45; = .044). We also demonstrate that this resulting signature was predictive of AML relapse with an area under the receiver operating characteristic curve of 0.71 within . All the relevant code is available at GitHub.
The texture features extracted from chromatin patterns of myeloblasts can predict post-HCT relapse and prognosticate RFS of patients with AML/MDS.
异基因造血干细胞移植(HCT)是急性髓系白血病(AML)和骨髓增生异常综合征(MDS)的一种根治性治疗方法。HCT 后复发是治疗失败的最常见原因,且与预后不良相关。基于病理学家的抽吸图像的视觉评估和手动髓样母细胞计数已被证明可预测 HCT 后复发。然而,这种方法既耗时又主观。本研究的前提是探索从髓样母细胞染色质模式中提取的计算机形态学和纹理特征是否有助于预测 HCT 后复发,并预测无复发生存(RFS)。
本研究收集了 92 例 AML/MDS 患者 HCT 后的瑞氏染色抽吸图像,这些患者被随机分配到训练集(n = 52)和验证集(n = 40)。首先,开发了一种基于深度学习的模型来分割髓样母细胞。然后,从抽吸载玻片图像上分割的髓样母细胞中提取了 214 个纹理和形状描述符。使用最小绝对收缩和选择算子(LASSO)与 Cox 回归模型生成基于髓样母细胞染色质模式纹理特征的风险评分。
该风险评分与 92 例患者中的 RFS 相关(风险比= 2.38;95%CI,1.4 至 3.95;P =.0008)和 40 例患者中的 RFS 相关(风险比= 1.57;95%CI,1.01 至 2.45;P =.044)。我们还证明,该特征签名可预测 AML 复发,在内部验证中,ROC 曲线下面积为 0.71。所有相关代码都可在 GitHub 上获得。
从髓样母细胞染色质模式中提取的纹理特征可预测 HCT 后复发,并预测 AML/MDS 患者的 RFS。